Epocrates, Inc. (NASDAQ:EPOC)

CAPS Rating: 5 out of 5

Results 1 - 5 of 5

Recs

0
Member Avatar modestus1 (< 20) Submitted: 9/2/2012 3:54:41 PM : Outperform Start Price: $8.88 EPOC Score: -6.11

Undervalued based on assets.

Recs

0
Member Avatar jrawk28 (< 20) Submitted: 1/15/2012 12:39:08 PM : Outperform Start Price: $8.90 EPOC Score: -18.06

Huge potential for future revenue, but so far untapped. 2013-2014 things should pick up as they capitalize on their user base of 50% of US physicians, the most valuable customers in the world.

Recs

1
Member Avatar TMFIPO2011 (< 20) Submitted: 7/6/2011 1:21:55 PM : Outperform Start Price: $17.57 EPOC Score: -87.46

**Physicians love Epocrates' mobile applications, because they reduce prescription errors, improve patient care, and save time.
**Epocrates is disrupting the face-to-face sales model used by pharma companies by offering a more targeted and cost-effective way to introduce physicians to new and existing drugs.
**The company has ridden its first-mover advantage to an 80% market share that reaches 45% of all U.S. physicians, and it benefits from a recurring revenue base to fund R&D for new products.

Recs

0
Member Avatar cemarsh1 (< 20) Submitted: 4/28/2011 12:34:17 AM : Outperform Start Price: $19.94 EPOC Score: -89.65

Growth potential of a medical/pharmaceutical data management company that has innovated electronic media platforms that facilitate physician, nurse, pharmacist capabilities

Recs

3
Member Avatar pbk100 (29.70) Submitted: 2/3/2011 11:58:59 AM : Outperform Start Price: $21.79 EPOC Score: -95.31

Fundamentals and monetization questions be damned - expect market frothiness over anything that can combine healthcare, information management and mobile devices, for a while at least.

Results 1 - 5 of 5

Featured Broker Partners


Advertisement